Orasolv (STO:OS)

MedPage Today  Aug 4  Comment 
(MedPage Today) -- No difference in OS compared with placebo after a median follow-up of 52 months
GenEng News  Jun 26  Comment 
Sumitomo Dainippon Pharma is unblinding the global Phase III BRIGHTER study evaluating its cancer stemness inhibitor napabucasin (BBI-608) in patients with gastric and gastroesophageal junction (GEJ) cancer on the recommendation of the study’s...
The Hindu Business Line  May 15  Comment 
The indiscriminate attack, which began Friday, struck banks, hospitals and government agencies, exploiting known vulnerabilities in old Microsoft computer OS



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki